| 4.59 0.43 (10.34%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.71 |
1-year : | 7.84 |
| Resists | First : | 5.75 |
Second : | 6.71 |
| Pivot price | 4.79 |
|||
| Supports | First : | 3.97 |
Second : | 2.86 |
| MAs | MA(5) : | 4.75  |
MA(20) : | 4.45 |
| MA(100) : | 3.01 |
MA(250) : | 4.15 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 57.2 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 8.56 | Low : | 1.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADVM ] has closed above bottom band by 36.7%. Bollinger Bands are 48.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.62 - 4.64 | 4.64 - 4.67 |
| Low: | 4.05 - 4.08 | 4.08 - 4.11 |
| Close: | 4.54 - 4.59 | 4.59 - 4.64 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Tue, 23 Sep 2025
HC Wainwright Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM) - MarketBeat
Mon, 22 Sep 2025
Adverum Biotechnologies Announces Completion of Screening - GlobeNewswire
Mon, 22 Sep 2025
Major Timeline Acceleration: Adverum's One-And-Done Eye Treatment Trial Hits Key Milestone 3 Months Early - Stock Titan
Sun, 21 Sep 2025
Trexquant Slashes Stake in Adverum Biotechnologies, Inc. (ADVM) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.136e+007 (%) |
| Held by Institutions | 13 (%) |
| Shares Short | 977 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7221e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -17 % |
| Return on Assets (ttm) | 513.2 % |
| Return on Equity (ttm) | -62.6 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -234.03 |
| EBITDA (p.s.) | -1.11643e+008 |
| Qtrly Earnings Growth | -8.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -131 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | -4.69 |
| Dividend | 0 |
| Forward Dividend | 1.02e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|